Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Conditions are right for biopharma M&A to break out

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 10, 2023 11:50am

148 Views

Post# 35440846

RE:RE:RE:RE:RE:Conditions are right for biopharma M&A to break out

There are a few here who might gain some insight from the the Greek philospher Epicurus' epistemology who, while agreeing to the Cynics' quest for honesty, correspondingly rejected their confused thought, "insolence and vulgarity", instead teaching that honesty must be coupled with courtesy and kindness.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China